The Morning Journal (Lorain, OH)

Wall Street posts gains after surge in deals

- By ALEX VEIGA and DAMIAN J. TROISE

Wall Street ended solidly higher following a burst of big corporate deals, clawing back losses from last week.

Wall Street kicked off the week with a broad rally Monday, clawing back much of the stock market’s losses from last week. The S&P 500 rose 1.3%, led by gains in technology, health care and financial stocks. Small company stocks were among the biggest gainers. The rally reversed a big slice of the index’s 2.5% slide last week, when the S&P 500 posted its biggest weekly decline since June. Treasury yields were mostly higher. The market’s strong start to the week is a reversal after a mostly downward shift in the market this month led by a sell-off in highflying tech stocks that many analysts said was long overdue.

“We’ve been due for a little bit of a pullback, and we’ve experience­d that so far in September,” said Terry Sandven, chief equity strategist at U.S. Bank Wealth Management. “We still have a positive outlook into the end of the year, but we believe market chop will be the norm.” The S&P 500 gained 42.57 points to 3,383.54. The Dow Jones Industrial Average rose 327.69 points, or 1.2%, to 27,993.33. The Nasdaq, which includes many tech stocks, picked up 203.11 points, or 1.9%, to 11,056.65. Small company stocks climbed more than the rest of the market, sending the Russell 2000 higher. The index rose 39.70 points, or 2.7%, to 1,536.97. Several big corporate deals helped put investors in a buying mood Monday. Nvidia jumped 5.8% after announcing plans to buy fellow chipmaker Arm Holdings in a deal worth up to $40 billion. Oracle climbed 4.3% after the business software maker beat out Microsoft to become the “trusted technology provider” of TikTok, the popular video-sharing app based in China. And the stock of Immunomedi­cs nearly doubled after the cancer drug specialist agreed to be acquired by Gilead Sciences in a $21 billion deal. Gilead shares rose 2.2%. AstraZenec­a added 0.5% following news over the weekend that clinical trials for the pharmaceut­ical company’s coronaviru­s vaccine will resume after being paused due to a reported sideeffect in a patient in the U.K. The vaccine is seen as one of the strongest contenders among the dozens of coronaviru­s vaccines being tested. Wall Street has been riding a surge in volatility the past couple of weeks as investors turned cautious following a five-month rally for stocks fueled largely by a runup in big tech companies. The pandemic accelerate­d the use of online services by businesses and individual­s, driving shares of Apple, Amazon, Microsoft, Zoom Video and other tech companies sharply higher through the summer. But concerns that the high-flying tech stocks had soared too high have put investors in a selling mood in September. The S&P 500 is down 3.3% so far this month, while the Nasdaq has pulled back 6.1%. “We know that momentum is going to slow a little bit, that’s expected,” said Esty Dwek, head of global market strategy at Natixis Investment Managers. “It wasn’t supposed to be, or it was never going to be a straight line without any bumps in the road.” Despite its September stumble, stocks retain much of their gains since setting record highs less than two weeks ago. The S&P 500 is up 4.7% for the year. The Nasdaq is up 23.2%. Even so, analysts expect more volatility for stocks in the months ahead as the market navigates uncertaint­y over the outcome of the election, pessimism that Democrats and Republican­s in Washington will be able to find a deal to send more aid to unemployed workers and an economy still struggling amid the pandemic. One big factor that remains in the stock market’s favor is the Federal Reserve, which continues to pump aid into the economy.

Newspapers in English

Newspapers from United States